Introduction {#Sec1}
============

The impact of ionizing radiation on mammalian cells depends significantly on the particle fluence of radiation per unit of time, so called dose-rate effects (DREs)^[@CR1]^. During protracted irradiation at lower dose-rates, induction of toxic DNA lesions along the particle track competes with DNA damage repair, which leads to reduced cell-killing^[@CR2]^. However, in recent decades, increased induction of mutation or chromosomal aberrations^[@CR3],[@CR4]^ and enhancement of cell-killing in a lower dose-rate range of 10--100 cGy/h^[@CR5]^ have been reported, so-called "inverse dose-rate effects (IDREs)". Under low-dose exposure, mammalian cells exhibit hyper radio-sensitivity (HRS) to doses with \<30 cGy which is believed to result from failure to arrest in G~2~^[@CR6],[@CR7]^, whilst intercellular signalling has also been reported to have the potential capacity to enhance cell-killing^[@CR8],[@CR9]^. Although the involvement of the cellular signalling in IDREs has been presumed, the underlying mechanism of IDREs remains unclear. Re-evaluation of the DREs on cell survival including IDREs is a crucial issue from the standpoints of radiation therapy and radiation protection^[@CR10]^.

The sparing effects of cell-killing under a lower dose-rate can be explained by sub-lethal damage repair (SLDR) during irradiation^[@CR2]^. SLDR during exposure also contributes to a decrease of the quadratic component in high-dose ranges^[@CR2]^. Under the confluent condition of cells represented as plateau phase (similar to conditions in tissue)^[@CR11]^, the cell-cycle distribution is mainly composed of cells in G~1~ phase. There have been some reports that the fraction of cells in G~2~/M phase gradually increases during protracted irradiation, i.e., at 60 cGy/h in tumour cell line of T98G (derived from human glioblastoma multiforma) and U373MG (derived from human glioblastoma astrocytoma) and at 100 cGy/h in CHO-K1 (derived from Chinese Hamster ovary)^[@CR5],[@CR12]^. As reported in our previous study, the fractionated regimen of 1 Gy per fraction at every 1 h time interval, which is similar to continuous exposure at 1.0 Gy/h, was used to discuss the cell-cycle change^[@CR12]^. In such an irradiation, the accumulation in G~2~/M phase under lower dose-rate may be associated with higher radio-sensitivity^[@CR12]^. In this regard, radio-sensitivity during exposure can be potentially modulated by not only intercellular signalling as suspected recently but also changes in cell-cycle distribution^[@CR13],[@CR14]^ including cell multiplication^[@CR15],[@CR16]^. Thus, it is necessary to investigate the change for various dose-rates at the level of *in vitro* experiments.

From the viewpoint of estimating dose-response curves, the curves can be described in general by taking account of SLDR rate deduced from a split-dose cell recovery^[@CR17],[@CR18]^. According to the previous reports^[@CR2],[@CR17],[@CR18]^, the repair half-time of SLD is cell type and cell condition specific, e.g., 0.985 h in CHO cells in plateau phase. The linear-quadratic (LQ) model with Lea-Catcheside time factor^[@CR19]^ or microdosimetric-kinetic (MK) model^[@CR17]^ have been used to analyse cell survival considering SLDR during irradiation at the level of cell populations. However, recent model analysis using the MK model suggests that rate of SLDR depends on dose-rate, in which the SLDR rate decreases as dose-rate lowers^[@CR20]^. This interpretation may be linked to cell-cycle changes, but there is currently no report with evidence to support that SLDR changes depending on dose-rate. Thus, the interest in this study is directed to the consideration of SLDR depending on dose-rate associated with experimentally determined cell-cycle distribution during irradiation.

In this study, we used the Chinese Hamster Ovary (CHO)-K1 cell line that does not exhibit low-dose HRS^[@CR21]^ and newly observed the dose-rate dependence of cell survival in relation to the change of cell-cycle distribution during irradiation at 3.0 Gy/h (1.5 Gy per fraction at every 30 min interval, 24 fractions) and 6.0 Gy/h (2.0 Gy per fraction at every 20 min interval, 36 fractions) in addition to our previous data at 1.0 Gy/h (1.0 Gy/fr at every 1 h time interval, 12 fractions). Combined with previous cell responses for 0.186, 1.0, 1.5, 10.8, 18.6, 60.0 Gy/h, here we re-evaluated the radio-sensitivity at the endpoint of cell survival and mean inactivation dose. Finally we show that the changes of radio-sensitivity in dose-response curves under continuous irradiation can be explained by changes of SLDR rate due to an increase of cells in S phase.

Model Overview {#Sec2}
==============

Methodology of Cell-Killing Model {#Sec3}
---------------------------------

In order to determine a fractionated regimen equivalent to a long-term continuous exposure and to predict DREs on cell survival, we used the microdosimetric-kinetic (MK) model for continuous irradiation^[@CR17]^. The MK model has been developed based on microdosimetry^[@CR22]^ and popular theory of damage behaviour^[@CR23],[@CR24]^ by comparing with several experimental data so far^[@CR2],[@CR12],[@CR17],[@CR18],[@CR20],[@CR25]--[@CR29]^. In this study, we further developed the MK model so as to consider change of DNA amount per nucleus and SLDR rate during irradiation, hereafter called the "integrated microdosimetric-kinetic (IMK) model".

Briefly, the MK model^[@CR17]^ subdivides the cell nucleus into a lot of micro-order territories (so-called domains) so as to incorporate microdosimetry^[@CR22]^. The shape of the domains is for simplicity defined as a sphere with radius from 0.5 to 1.0 μm^[@CR17],[@CR20]^ and the local energy deposition along radiation particle track can be evaluated in terms of tissue equivalent proportional counter (TEPC) measurements^[@CR27]^ or Monte Carlo simulations^[@CR27],[@CR30]^. DNA damage which may be toxic to the cell is represented as a potentially lethal lesion (PLL), induced in a domain packaging DNA amount of *g* (kg) along the particle track with local dose deposition (as in Gy) per domain *z*. The DNA lesion (PLL) can gradually transform into lethal lesion (LL) or be repaired until no PLL remain:(i)A PLL may transform into a lethal lesion (LL) via a first-order process at a constant rate *a* (h^−1^)(ii)Two PLLs may interact and transform into a lethal lesion (LL) via a second-order process at a constant rate *b*~d~ (h^−1^)(iii)A PLL may be repaired via a first-order process at constant rate *c* (h^−1^).

The rate equation for the number of PLLs per domain after acute exposure *x*~d~(*t*) is given by$$\documentclass[12pt]{minimal}
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This can be solved as exponential function expressed by$$\documentclass[12pt]{minimal}
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Let us consider a continuous exposure to a cell population with dose-delivery time *T* (h) and dose-rate $\documentclass[12pt]{minimal}
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                \begin{document}$$\dot{D}$$\end{document}$ (Gy/h). To model this, during the dose-delivery, specific energy (*z*~1~, *z*~2~, ..., *z*~N~) is discontinuously deposited in a domain with amount of DNA (*g*~1~, *g*~2~, ..., *g*~N~) at each sub-section of dose-delivery time (\[0, *ΔT*), \[*ΔT*, 2*ΔT*), ..., \[(*N* − 1)*ΔT*, *NΔT*)), thus we obtain the relation of *T* = *N*Δ*T*, where *N* is the number of sub sections in total dose-delivery time *T*^[@CR12],[@CR17]^. In this study, we newly assumed that the rate of SLDR (*c*~1~, *c*~2~, ..., *c*~N~) changes at each sub-section of *T* (\[0, *ΔT*), \[*ΔT*, 2*ΔT*), ..., \[(*N* − 1)*ΔT*, *NΔT*)). Thus, the number of PLLs per domain *x*~*d*~(*t*) can be expressed based on Eq. ([2](#Equ2){ref-type=""}) as$$\documentclass[12pt]{minimal}
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Whilst PLLs' induction competes with SLDR during dose-delivery, LLs gradually increase according to the next rate equation as$$\documentclass[12pt]{minimal}
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In Eq. ([6](#Equ6){ref-type=""}), the value of *a* is a few percent of *c*~*n*~^[@CR17],[@CR20]^, thus (*a* + *c*~*n*~) can be simply approximated by *c*~*n*~. Let \<*w*~d~\> and \<*w*\>~T~ be the average number of lethal lesions per domain and the average number of LLs per nucleus, respectively. Considering the mean dose per nucleus \<*z*~*n*~\> and the mean amount of DNA per nucleus \<*G*~*n*~\> at the timing of *t* = (*n* *−* 1)*ΔT* and assuming that the absorbed dose rate is constant (\<*z*~1~\> = \<*z*~2~\> = , ..., = \<*z*~*n*~\> = $\documentclass[12pt]{minimal}
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Link to the LQ model with or without Lea-Catcheside time factor {#Sec4}
---------------------------------------------------------------

The present model can be linked to the LQ model with the classic Lea-Catcheside time factor^[@CR19]^. Here, we assume a special case that cell condition (amount of DNA and SLDR rate) does not change during irradiation, i.e., 〈*G*~1~〉 = 〈*G*~2~〉 = ... = 〈*G*~*N*~〉 = 〈*G*〉 = constant, *c*~1~ = *c*~2~ = ... = *c*~*N*~ = *c* = constant, *α*~*n*~ = *α*~0~ = constant and *β*~*n*~ = *β*~*nm*~ = *β*~0~ = constant. Eq. ([10](#Equ18){ref-type=""}) can be expressed by$$\documentclass[12pt]{minimal}
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Eq. ([13](#Equ21){ref-type=""}) is the cell-killing model including the Lea-Catcheside time factor including SLDR rate. Further if we consider the acute exposure ($\documentclass[12pt]{minimal}
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                \begin{document}$$\begin{array}{rcl}-\mathrm{ln}\,{S} & = & ({\alpha }_{0}+{\gamma }{\beta }_{0})D+{\beta }_{0}{D}^{2}\\  & = & \alpha D+\beta {D}^{2}.\end{array}$$\end{document}$$Thus, the traditional linear-quadratic (LQ) model approximates this model for the case of acute exposure without considering dose-delivery time^[@CR2],[@CR19]^. In this study, in comparison between dose-response curves described by Eq. ([11](#Equ19){ref-type=""}) and by Eq. ([13](#Equ21){ref-type=""}), we planned a fractionated regimen equivalent to the continuous exposure with a constant dose rate (Fig. [1B](#Fig1){ref-type="fig"}) as previously described^[@CR12]^.

Materials and Methods {#Sec5}
=====================

Cell Culture and Irradiation Condition {#Sec6}
--------------------------------------

A mammalian cell line, Chinese Hamster Ovary (CHO)-K1 was obtained from RIKEN Bio Resource Center, Japan (RBC0285). This type of cell line was selected because it does not exhibit HRS^[@CR21]^. The cells were maintained in Dulbecco's modified Eagle's (DMEM, Sigma Life Science) supplemented with 10% fetal bovine serum (FBS, Equitech-Bio Inc.) and 1% penicillin/streptomycin (Sigma Life Science) at 37 °C in humidified 95% air and 5% CO~2~.

To investigate cell responses after a long-term exposure, five days prior to irradiation 4 × 10^5^ cells were seeded onto the cell culture dish with 60 mm diameter (Nippon Genetics) to obtain the cells under plateau phase. In parallel, to quantify the dependence of SLDR rates on cell-cycle distribution, we prepared two cell-cycle distributions for plateau phase and logarithmic growth phase five days and one day after seeding, respectively.

Irradiation Condition {#Sec7}
---------------------

Standard radiation, 250 kVp X-rays (Stabilipan, Siemens, Concord, CA), was used to irradiate the cultured cells. The dose rate in air at the surface of cell culture was measured by using Farmer-type ionizing radiation chamber (model NE2581, Nuclear Enterprises Ltd) and was converted to the dose rate in water (4.31 Gy/min) according to the dose protocol TRS277^[@CR31]^. From the comparison between Eqs ([11](#Equ19){ref-type=""}) and ([13](#Equ21){ref-type=""}), the practical fractionation regimens equivalent to the average dose rates of 3.0 Gy/h and 6.0 Gy/h were newly determined at a visual level (the *R*^2^ value is found to be 0.999), which were 1.5 Gy per fraction at 30 min interval for 3.0 Gy/h and 2.0 Gy at 20 min interval for 6.0 Gy/h (Fig. [1B](#Fig1){ref-type="fig"}).

Flow-Cytometric Analysis of Cell-Cycle Distribution {#Sec8}
---------------------------------------------------

For each dose-rate exposure, 1 × 10^6^ cells were harvested at 0, 2, 4, 6, 8, 10, 12 h after the start of irradiation and fixed with 70% ethanol, and then kept at 4 °C for at least 2 h. After a centrifugation, the cells were re-suspended in 1 ml phosphate-buffered saline (PBS) (*−*). After a centrifugation again, the DNA was stained with 0.5 ml FxCycle^TM^ propidium iodide (PI)/RNase staining solution (Life Technologies) including 0.2% v/v triton X for 15 min in the dark at room temperature. Cell-cycle distribution was then obtained by using the Attune acoustic focusing flow cytometer (Applied Biosystems by Life Technologies TM).

The fluorescence intensity emitted from the DNA in a nucleus was normalized by that from the DNA contained in a cell in G~0~/G~1~ phase. The cell-cycle distribution (fractions of the cells in G~0~/G~1~, S and G~2~/M) was then obtained from the DNA profile. All sets of cell-cycle study were performed three times. By using the Tukey-Kramer method^[@CR32]^, we evaluated if there is significant difference in the change of cell-cycle distribution from the control group (before irradiation at *t* = 0 (h)).

Clonogenic Survival Assay {#Sec9}
-------------------------

After exposure to the regimen equivalent to 3.0 and 6.0 Gy/h, irradiated cells were trypsinized immediately and the appropriate number of cells was reseeded into a cell culture dish with 60 mm diameter (Nippon Genetics). Culture medium was exchanged every two days and the cells were cultured for 10--14 days. The colonies were fixed with methanol and were stained with 2% Giemsa solution (Kanto Chemical Co. Inc.) Survival fraction was obtained from the ratio of colony number of irradiated cells to that of non-irradiated cells (control cells). The plating efficiency for control cells was 38.8 ± 9.2% (mean ± standard deviation), which was given by 27 dishes (the assay was performed three times for each dose-rate, and three dishes were used in one assay).

Determination of SLDR Rate from a Split-Dose Cell Recovery Curve {#Sec10}
----------------------------------------------------------------

The constant rate of SLDR was obtained from cell recovery curve of cell survival in a split-dose experiment. Let us consider a case of exposing a cell population to equal acute doses with *D*~1~ (=*\<z*~1~\>) (Gy) and *D*~2~ (=*\<z*~2~\>) (Gy) at the interval of *τ* (=*ΔT*) (h). The surviving fraction for a split-dose exposure is given by$$\documentclass[12pt]{minimal}
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On one hand, subtracting Eq. ([18](#Equ28){ref-type=""}) from Eq. ([17](#Equ27){ref-type=""}) gives$$\documentclass[12pt]{minimal}
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On the other hand, taking the derivative of Eq. ([16](#Equ26){ref-type=""}) and taking the limit of d*S*/d*τ* as *τ* tends to 0, we have$$\documentclass[12pt]{minimal}
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Thus we can deduce the cell-specific parameter of SLDR rate by using the following equation,$$\documentclass[12pt]{minimal}
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Cell recovery curves for a split-dose experiment are always influenced by re-distribution and cell proliferation^[@CR17],[@CR18]^. Based on the previous reports to deduce (*a* + *c*) value^[@CR17],[@CR18]^, to avoid the influences of re-distribution and repopulation, the initial slope d*S*/d*τ* and *S*($\documentclass[12pt]{minimal}
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                \begin{document}$$\infty $$\end{document}$) were determined from experimental surviving fraction by taking the gradient from 0 to 1 h, and maximum survival was taken at the 2 h time interval. Because the value of *a* is a few percent of *c*^[@CR17],[@CR20]^, thus the rate of SLDR can be approximated by *c* value. Whilst the SLDR rate for plateau phase of CHO-K1 was taken from our previous report^[@CR12]^, that for logarithmic growth phase was deduced by Eq. ([21](#Equ31){ref-type=""}) and a cell recovery curve reported in the literature^[@CR33]^.

Change of DNA Amount and SLDR Rate During Irradiation {#Sec11}
-----------------------------------------------------

Experimentally determined changes of relative DNA amount per nucleus during irradiation 〈*G*~*n*~〉/〈*G*~1~〉 were input into Eq. ([10](#Equ18){ref-type=""}) as previously described^[@CR12]^. Additionally, in this study we assumed that SLDR rate represented by *c*~*n*~ (h^−1^) changes during irradiation depending on fraction of cells in S phase, which has a high repair efficiency^[@CR34]^ leading to lower radio-sensitivity^[@CR14],[@CR35]^. We estimated the differential rate of SLDR, and then deduced the change of SLDR rate per fraction of cells in S phase during exposure from experimental cell-cycle distributions using the following equation$$\documentclass[12pt]{minimal}
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                \begin{document}$${c}_{n}={c}_{{\rm{0}}}+\frac{{\rm{d}}c}{{\rm{d}}{N}_{{\rm{S}}}}{\rm{\Delta }}{N}_{S}(t),$$\end{document}$$where *t* is the time after the start of irradiation (h), *c*~0~ is the SLDR rate at *t* = 0, d*c*/d*N*~*S*~ is the differential rate of SLDR per fraction of cells in S phase, and *N*~*S*~ is the fraction of cells in S phase. In this study, d*c*/d*N*~*S*~ was determined from the subtractions of SLDR and fraction of cells in S phase for plateau and logarithmic growth phases, and the change of cell fraction in S phase Δ*N*~*S*~ was obtained from cell-cycle study during fractionated exposures.

Comparison Between Model and Measured Cell Survival {#Sec12}
---------------------------------------------------

To investigate the influence of change of repair rate associated with cell-cycle distribution on cell survival curve, we compared the dose-response curves estimated by Eq. ([10](#Equ18){ref-type=""}) with measured clonogenic cell survival data. We used model parameters for the CHO-K1 cell line after exposure with 250 kVp X-rays which have been already published^[@CR12]^. The values of the parameters are summarized in Table [1](#Tab1){ref-type="table"}. In the set of parameters, DNA contents represented by 〈*G*〉 and 〈*G*^2^〉 were obtained within the performed cell-cycle experiment, and the set of physical parameters (*γ*, *y*~*D*~, *r*~d~, *ρ*) was taken from the previous reports^[@CR12]^. Here, we assumed that the constant rates of *a* (h^−1^) and *b*~d~ (h^−1^) are cell-specific parameters independent of the cell-cycle distribution for simplicity, and the cell survival curve was calculated considering the change of mean DNA amount per nucleus and SLDR rate during the exposure at various dose-rates.Table 1Model parameters for two cell conditions in CHO-K1 cell line.Model ParametersCell ConditionPlateau PhaseLogarithmic Growth Phase*α*~1~ = *A*~1~〈*G*~1~〉(=*α*~0~) (Gy^−1^)0.155 ± 0.0270.075 ± 0.025*β*~1~ = *B*~1~〈*G*~1~^2^〉 (=*β*~0~) (Gy^−2^)0.048 ± 0.0030.028 ± 0.008$\documentclass[12pt]{minimal}
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                \begin{document}$$\gamma ={y}_{D}/({\rm{\rho }}{\rm{\pi }}{r}_{{\rm{d}}}^{{\rm{2}}})\,({\rm{Gy}})$$\end{document}$0.924 (250 kVp)0.924 (250 kVp)**Each PhaseCell Cycle distribution \[%\]Plateau PhaseLogarithmic Growth Phase**G~0~/G~1~72.7 ± 6.637.6 ± 3.8S14.9 ± 2.352.4 ± 4.5G~2~/M12.4 ± 3.911.4 ± 0.7The set of values for plateau phase was obtained from our previous report^[@CR12]^. In these parameters, *a* is a few percentage of *c*^[@CR17],[@CR20]^. Relative mean DNA amount per nucleus was normalized by that for plateau phase. The set of parameters for logarithmic growth phase was converted from that for plateau phase (SD was deduced by error propagation). In the parameters, (*a* + *c*) value for logarithmic phase was deduced from an experimental cell recovery data^[@CR33]^, and DNA amount represented by 〈*G*〉 and 〈*G*^2^〉 was obtained within the performed cell-cycle experiment. The set of physical parameters (*γ*, *y*~*D*~, *r*~d~, *ρ*) was taken from the previous reports^[@CR12]^.

To test the assumption of fixed *a* and *b*~d~ values, we compared the estimated survival curve with experimental one for two cell conditions of plateau and logarithmic growth phases. Whilst the set of parameters (*α*~0~, *β*~0~, *a* + *c*) for plateau phase is summarized in the left side of Table [1](#Tab1){ref-type="table"}, the set for logarithmic growth phase is given by the ratios of DNA amount measured in this work and SLDR rate deduced by Eq. ([21](#Equ31){ref-type=""}).

The fit quality of the model used in this study was evaluated from reduced chi-square value expressed by$$\documentclass[12pt]{minimal}
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Mean Inactivation Doses {#Sec13}
-----------------------

To investigate survival curves of the CHO-K1 cells, we further used the concept of the mean inactivation dose $\documentclass[12pt]{minimal}
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Results {#Sec14}
=======

Change in Cell-Cycle Distribution during Exposure for Various Dose Rates {#Sec15}
------------------------------------------------------------------------

Two fractionated regimens equivalent to the continuous exposures with 3.0 and 6.0 Gy/h were used to investigate DREs on cell-cycle distribution during exposure. Figure [2](#Fig2){ref-type="fig"} shows the change in cell-cycle distribution during the exposure for various dose-rates, in which data at 3.0 Gy/h and 6.0 Gy/h were newly measured in this study. The data at 0.0 Gy/h, 0.186 Gy/h and 1.0 Gy/h were obtained from our previous investigation^[@CR12]^.Figure 2Cell-cycle distribution during exposure at various dose-rates. (**A**) is for the change of cell faction in G~0~/G~1~ phase, (**B**) is for that in S phase and (**C**) is for that in G~2~/M phase. The data for 3.0 and 6.0 Gy/h were newly measured in the present flow-cytometric analysis and the other sets of data were taken from our previous report^[@CR12]^. The symbol \* represents P \< 0.05 significant change compared with the data at just start of irradiation (0 h). The error bar represents the standard deviation deduced from three independent experiments. In addition, we confirmed there is no significant difference of cell-cycle distribution at the starting time of irradiation among control (0.00 Gy/h), 0.186 Gy/h, 1.0 Gy/h, 3.0 Gy/h and 6.0 Gy/h by using the Tukey-Kramer method.

During the exposure with lower dose-rates such as 1.0 Gy/h and 0.186 Gy/h, the fraction of the cells in G~2~/M phase gradually and slightly increased with increasing fractions. During the exposure with 3.0 Gy/h, significant increases of cell fraction in S phase were observed up to 6 h after the start of fractionated irradiation, whilst the subtle accumulation of the cells in G~2~/M phase was observed. During the exposure with the highest dose rate, 6.0 Gy/h, there is no change in cell-cycle distribution until 8 h after the start of irradiation. However, at 10 h after the start of irradiation, significant increases of cell fraction in S phase and G~2~/M phase were observed.

SLDR Rate during Exposure and Prediction of Cell Survival {#Sec16}
---------------------------------------------------------

To investigate the influence of the change in cell-cycle distribution on cell survival, we obtained the change of mean DNA amount per nucleus and the SLDR rate during exposure from flow-cytometric analysis of DNA profiles. In the upper panels of Fig. [3](#Fig3){ref-type="fig"}, the DNA profile for plateau phase and for logarithmic growth phase (Fig. [3A](#Fig3){ref-type="fig"}) and the procedure to deduce the SLDR rate for logarithmic growth phase from Eq. ([21](#Equ31){ref-type=""}) with a split-dose cell recovery^[@CR33]^ (Fig. [3B](#Fig3){ref-type="fig"}) are presented. The details of cell-cycle distribution for both phases and SLDR rates *c*~1~ were also listed in Table [1](#Tab1){ref-type="table"}. The SLDR rate for logarithmic growth phase (1.782 ± 0.441 h^−1^) is in good agreement with that of the previous report (1.72 (1.27--2.59) h^−1^) by Hawkins^[@CR17]^. Based on the cell-cycle study (Fig. [2](#Fig2){ref-type="fig"}) and the rate of SLDR via cell-killing model (Fig. [3B](#Fig3){ref-type="fig"}), we obtained the change of mean DNA amount per nucleus (Fig. [3C](#Fig3){ref-type="fig"}) and estimated the S-phase dependent SLDR rate during exposure according to Eq. ([22](#Equ32){ref-type=""}), as shown in Fig. [3D](#Fig3){ref-type="fig"}. From the experimental data about fraction of cells in S phase and SLDR rate for plateau and logarithmic growth phases (Table [1](#Tab1){ref-type="table"}), we deduced the value of d*c*/d*N*~*S*~ = 0.0287 ± 0.0128 (h^−1^/%).Figure 3Cell condition (DNA profile and SLDR rate) input into the present model. (**A**) shows DNA profile and cell-cycle distribution for plateau and logarithmic growth phase in CHO-K1 cell line, (**B**) shows procedure to deduce the rate of SLDR for logarithmic growth phase, (**C**) and (**D**) show the change of average DNA amount per nucleus and SLDR rate during protracted exposure, respectively, for various dose-rates. In Fig. 3B, a split-dose cell recovery data (5 Gy + 10 Gy) was taken from ref.^[@CR33]^ and we deduced (*a* + *c*) value based on Eq. ([21](#Equ31){ref-type=""}) from d*S*/dτ, *S*(0) and *S*($\documentclass[12pt]{minimal}
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                \begin{document}$$\infty $$\end{document}$). Here the data for 0.0, 0.186 and 1.0 Gy/h were taken from our previous investigation^[@CR12]^. In Fig. 3C,D, whilst the symbols represent measured mean DNA contents and variation of S-phase fraction, the lines are the interpolated curve by spline. The constant rates for the exposure to 0.0, 0.186 and 1.0 Gy/h of SLDR were adopted because there is no significant change of S-phase fraction.

Figure [4](#Fig4){ref-type="fig"} shows the comparison between the cell survival curve described by the present model (IMK model) and the clonogenic survival data for various dose-rates of 0.186--60.0 Gy/h. This includes both newly obtained dose-response curves after the exposure with 3.0 and 6.0 Gy/h (Fig. [4D,E](#Fig4){ref-type="fig"}) and re-analysed curves in comparison with reference data (Fig. [4A--C](#Fig4){ref-type="fig"} and [F--H](#Fig4){ref-type="fig"})^[@CR38]^. In Fig. [4](#Fig4){ref-type="fig"}, dotted lines and solid lines represent respectively the model prediction according to Eq. ([13](#Equ21){ref-type=""}) with a constant rate of (*a* + *c*)  =  0.704 (h^−1^) and Eq. ([10](#Equ18){ref-type=""}) with the experimental-based variable SLDR rate during exposure as well as DNA amount changing shown in Fig. [3C,D](#Fig3){ref-type="fig"}, whilst symbols denote the experimental cell survival including reference data^[@CR38]^. In Fig. [4D](#Fig4){ref-type="fig"} for 3.0 Gy/h, unexpected radio-resistance (increase of cell survival) was observed compared to the curve predicted by Eq. ([13](#Equ21){ref-type=""}). This is attributable to both the change of SLDR rate and DNA amount per nucleus during exposure (Fig. [3C,D](#Fig3){ref-type="fig"}). The cell survival curves (in Fig. [4B,D](#Fig4){ref-type="fig"} and [E](#Fig4){ref-type="fig"}) described by the IMK model for 1.0, 3.0 and 6.0 Gy/h with the both factors were in better agreement with experimental data (Table [2](#Tab2){ref-type="table"}). Applying the time course of DNA contents and SLDR rate under 6.0 Gy/h into the model prediction of cell survival for a higher dose rate of 10.8 Gy/h, the surviving fraction estimated by the IMK model is slightly higher than that by the previous model (Fig. [4F](#Fig4){ref-type="fig"}). Figure [4G,H](#Fig4){ref-type="fig"} represent the cases in higher dose rates (18.6 and 60.0 Gy/h), where the dose-delivery time is relatively short. We applied the cell-cycle kinetics under higher dose-rate of 6.0 Gy/h to predict the dose-response curve for 18.6 and 60.0 Gy/h.Figure 4Comparison between the clonogenic survival data and the model prediction. Whilst the symbols denote the survival data by our work and reference data, dotted line and solid line represent the model estimations with a constant rate of (*a* + *c*)  =  0.704 (h^−1^) and with changing rate of *c* based on Fig. [3D](#Fig3){ref-type="fig"}, respectively. The data for 3.0 and 6.0 Gy/h were newly observed in this paper. The fit qualities of the model for 1.0 Gy/h, 3.0 Gy/h and 6.0 Gy/h are summarized in Table [2](#Tab2){ref-type="table"}.Table 2Statistical evaluation of fit quality of the present model.Dose Rate (DR)*χ*^2^ valueConstant SLDR\
(*a* + *c*) = 0.704DNA amount & changing SLDR1.00 Gy/h9.27 × 10^−1^5.33 × 10^−1^3.00 Gy/h1.09 × 10^1^3.41 × 10^0^6.00 Gy/h1.18 × 10^0^8.28 × 10^−1^Sum *χ*^2^ value1.30 × 10^1^4.77 × 10^0^The *χ*^2^ value was calculated by using Eq. ([23](#Equ33){ref-type=""}).

Figure [4I](#Fig4){ref-type="fig"} shows the collection of all of the parts of dose-response curve estimated by the present model (following Eq. ([10](#Equ18){ref-type=""}) and change of cell conditions given by Fig. [3C,D](#Fig3){ref-type="fig"}) in comparison with the experimental data. The cell survival increases as the dose-rate decreases by virtue of SLDR during dose-delivery time. However, focusing on the dose-rate range of 1.0--3.0 Gy/h, the inverse dose-rate effects (IDREs) can be observed, in which a radio-resistance resulted from cell accumulation in S phase for 3.0 Gy/h whilst a higher radio-sensitivity induced by cell accumulation in G~2~/M phase for around 1.0 Gy. These results suggest that the cell-cycle dynamics during exposure may modulate the cell survival curve, whilst it is shown that the cell-killing model with traditional Lea-Catcheside time factor (Eq. ([13](#Equ21){ref-type=""})) is a special case for no cell-cycle change during exposure.

Evaluation of Dose-Rate Effects on Mean Inactivation Dose {#Sec17}
---------------------------------------------------------

The DREs on cell survival shown in Fig. [4](#Fig4){ref-type="fig"} were next evaluated by means of the mean inactivation dose $\documentclass[12pt]{minimal}
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                \begin{document}$$\bar{D}$$\end{document}$ was represented as red symbol. In this study, we predicted the DREs by using two SLDR approach, one for a constant (*a* + *c*) value of 0.704 (h^−1^) and the other for the variable (*a* + *c*) values during irradiation shown in Fig. [3D](#Fig3){ref-type="fig"}. In Fig. [5](#Fig5){ref-type="fig"}, whilst the $\documentclass[12pt]{minimal}
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                \begin{document}$$\bar{D}$$\end{document}$ value^[@CR36]^ and the possibility of experimental outliers, we cannot clearly judge if there is a reversal in radio-sensitivity at dose-rates around 10.8 Gy/h.Figure 5Mean inactivation dose $\documentclass[12pt]{minimal}
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                \begin{document}$$\bar{D}$$\end{document}$ calculated by using the cell-killing model formula Eq. ([13](#Equ21){ref-type=""}) with constant (*a* + *c*) value of 0.704 (h^−1^), and blue line (with symbols) is the $\documentclass[12pt]{minimal}
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                \begin{document}$$\bar{D}$$\end{document}$ calculated by using the model (Eq. ([10](#Equ18){ref-type=""})) with variable repair rate, *c*, during the exposure. It is noted that there is concave characteristics in dose-rate range of around 1.5--3.0 Gy/h. The $\documentclass[12pt]{minimal}
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                \begin{document}$$\bar{D}$$\end{document}$ and *R*^2^ values were calculated by using Eqs ([24](#Equ34){ref-type=""}) and ([25](#Equ35){ref-type=""}), respectively.

Testing the Assumption of Cell-Specific Model Parameters Independent of the Cell Cycle {#Sec18}
--------------------------------------------------------------------------------------

Testing the Assumption of Cell-Specific Model Parameters Independent of the Cell Cycle. Here we assumed that the constant rates of *a* (h^−1^) and *b*~d~ (h^−1^) are cell-specific parameters independent of the cell-cycle distribution. To check if this assumption is correct or not, we further compared Eq. ([15](#Equ25){ref-type=""}) with measured cell survival after acute exposure under two cell phases, plateau phase and logarithmic growth phase (Fig. [6A](#Fig6){ref-type="fig"}). The set of parameters (*α*~0~, *β*~0~) for plateau phase was converted to those in logarithmic growth phase by using the ratios of DNA amount and SLDR rate, which is listed in Table [1](#Tab1){ref-type="table"}. In Fig. [6B](#Fig6){ref-type="fig"}, we also compared the cell surviving fractions for both phases^[@CR2],[@CR38]--[@CR44]^ with the estimation by using the converted model parameters for logarithmic growth phase. In this comparison, the difference between dose-response curves in plateau phase and logarithmic growth phase is explainable by taking account of the mean DNA amount per nucleus and SLDR rate, which validates partly the interpretation that the values of *a* (h^−1^) and *b*~d~ (h^−1^) don't depend on the cell condition.

Discussion {#Sec19}
==========

CHO-K1 cells show the following responses: (i) accumulation of cells in G~2~ during exposure with 1.0 Gy/h^[@CR12]^, (ii) delay of DNA synthesis and accumulation of the cells in S and G~2~ during exposure with 3.0 Gy/h and (iii) no significant change of cell-cycle distribution until 8 h after the start of exposure to 6.0 Gy/h (Fig. [2](#Fig2){ref-type="fig"}). The increase of cells in S phase during the exposure to 3.0 Gy/h might be attributed to the DNA damage response in S phase checkpoint^[@CR45]^. In contrast, according to previous investigations^[@CR46]^, the threshold dose for blocking cell cycle progression at the G~1~/S checkpoint is considerably higher than G~2~/M checkpoint. For the case of CHO cells, Lee *et al*. reported a p53-independent damage-sensing checkpoint which operates to prevent late G~1~ or early S-phase^[@CR47]^. In this regard, we interpreted that whilst the G~1~/S checkpoint system was not activated under exposure with 3.0 Gy/h, it was activated under exposure with 6.0 Gy/h (Fig. [2A](#Fig2){ref-type="fig"}).

From the measured cell-cycle distribution (Fig. [2](#Fig2){ref-type="fig"}), we estimated S-phase dependent SLDR rates (Fig. [3D](#Fig3){ref-type="fig"}) and subsequently described cell survival curves in comparison with the MK model with a constant SLDR rate of (*a* + *c*)  =  0.704 (h^−1^) (dotted line in Fig. [4](#Fig4){ref-type="fig"}) and also with a changing rate of SLDR (solid line in Fig. [4](#Fig4){ref-type="fig"}). From the statistical evaluation by using the model (Table [2](#Tab2){ref-type="table"}), the changing rate of repair *c* plays an important role for describing not only the DREs on cell survival curve with reduction of chi-square value (Fig. [4](#Fig4){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}) but also mean inactivation dose with reasonable *R*^2^ value (Fig. [5](#Fig5){ref-type="fig"}). This suggests that the magnitude of DNA damage might trigger the series of repair proteins activation, depending on dose rate^[@CR48]^. Here, the misrepair rates, *a* (h^−1^) and *b*~d~ (h^−1^) were assumed to be constant cell-specific parameters not depending on cell condition. On this basis, we converted the set of parameters for plateau phase to that for logarithmic growth phase (Table [1](#Tab1){ref-type="table"}), to reproduce the surviving fraction under the both phases in the methodology of the IMK model (Fig. [6B](#Fig6){ref-type="fig"}). According to the previous model assessment by Hawkins, the value of (*a* + *c*) is mainly composed of non-homologous end joining (NHEJ)^[@CR20]^. However, it is known that Homologous Recombination (HR), a more accurate repair process, becomes more important in S phase, which may contribute to the observed increased resistance in S phase. Traditionally, there are two types of definition for repair kinetics, i.e., SLDR for dose fractionation and potentially lethal damage repair (PLDR) for treatment such as hypertonic saline. Several attempts have been made to understand whether or not SLDR and PLDR are the same^[@CR49]^. To this subject, the present model study (Figs [4](#Fig4){ref-type="fig"} and [6B](#Fig6){ref-type="fig"}) may support that SLDR and PLDR are similar to each other.Figure 6Dose-response curves for different cell culture conditions. (**A**) Upper panels represent microscopic images and DNA profiles for (i) plateau and (ii) logarithmic growth phases, respectively. Bottom figure is cell growth curve of CHO-K1 cell line to make the two cell conditions. (**B**) Dose-response curves were predicted by considering DNA contents per nucleus and the rate of SLDR for the two different phases. The set of parameters for logarithmic growth phase listed in Table [1](#Tab1){ref-type="table"} was deduced from that for plateau phase with the cell condition (DNA content and SLDR rate). The estimated curves were compared with experimental data after irradiation with 250 kVp X-rays^[@CR2],[@CR38]--[@CR44]^ to check the assumption in this study.

The model proposed in this study follows the linear-quadratic (LQ) formalism, which is convenient for calculating *α/β* and biological effective dose (BED)^[@CR50]^ considering the Lea-Catcheside time factor^[@CR19],[@CR51]^. The modelling approach for predicting cell-cycle dependent survival of V79 cells was also presented in a similar manner to that with a small set of parameters by Hufnagl *et al*.^[@CR53]^. In comparison to their model, the present IMK model enables us to describe cell-cycle dependent dose-response curve (Fig. [4](#Fig4){ref-type="fig"}) for not only acute exposure but also long-term exposure (Fig. [6B](#Fig6){ref-type="fig"}). However, the DNA damage repair kinetics is complex and is generally quantified by two exponential components for rejoining of the broken ends of DNA^[@CR52]^. If the complex repair kinetics is essential, more detailed mechanistic modelling such as the computational modelling by McMahon *et al*.^[@CR54],[@CR55]^ may be more suitable to understand the underlying radiation biology. As for clarifying the underlying mechanism of damage repair system, further investigation about the relation between SLDR and repairs function (NHEJ, HR, etc.) is necessary in various cell lines.

The model and data exhibit IDREs in the dose-rate range of 1.0--3.0 Gy/h, attributable to increases in SLDR during irradiation. According to the previous investigation about dependence of cell phase on cell killing^[@CR14]^, S phase (including late S phase) is the most radio-resistant. This tendency was found in the comparison between the experiment and the model in Fig. [4D--F](#Fig4){ref-type="fig"}. In addition, the accumulation of cells in the relatively more radio-sensitive phase of G~2~/M^[@CR12],[@CR14],[@CR56]^ contributes to the modulation of cell survival curve, leading to the reversal of DREs as shown in Fig. [4I](#Fig4){ref-type="fig"}. Supported by the dose-response curve in Fig. [4I](#Fig4){ref-type="fig"}, the mean inactivation dose in Fig. [5](#Fig5){ref-type="fig"} indicates the existence of IDREs as well. Considering these results, the combination of the accumulations of cells in S phase and G~2~/M phase is possibly responsible for IDREs.

IDREs on cell killing have been previously observed in dose-rate range of below 1.0 Gy/h^[@CR5],[@CR57]^, and other reports have shown higher mutant frequencies at dose-rates lower than 0.1--1 cGy/min^[@CR58]^. This previously observed dose-rate range is different from that we observed in this study. Other potential mechanisms, such as cumulative low-dose HRS after fractionated exposures has a possibility to induce this reversal in radio-sensitivity^[@CR57]--[@CR60]^, however the CHO-K1 cell line does not exhibit this behaviour^[@CR21]^. From the present study and the previous reports, it is likely that the dose-rate range for IDREs related to cell-cycle effects is higher than that related with low-dose HRS. Further model development for the cumulative low-dose HRS based on more detailed mechanistic evidence about the time course of the HRS is necessary.

In summary, we investigated the radio-sensitivity after the protracted exposure for various dose rates. Focusing on cell-cycle distribution, the experimental results suggested that the CHO-K1 cells show following responses: (1) an accumulation of the cells in G~2~ during exposure with lower dose rate (e.g., 1.0 Gy/h), (2) the delay of DNA synthesis and an accumulation of the cells in S/G~2~ during the exposure with intermediate dose rates (e.g., 3.0 Gy/h), and (3) the blocks of cell cycle progressing in whole checkpoints (G~1~/S and G~2~/M checkpoints) and the delay of DNA synthesis during the exposure with higher dose (e.g., 6.0 Gy/h). A greater radio-resistance after the exposure with 3.0 Gy/h was observed and this tendency was interpreted as increases in SLDR rate associated with the fraction of cells in S phase. Taking account of both higher radio-sensitivity under 1.0 Gy/h exposure and the radio-resistance after exposure to 3.0 Gy/h, the changes in cell-cycle distribution during exposure modulate the cell survival curve and are possibly responsible for IDREs. This study would contribute to a quantitative understanding of radio-sensitivity after long-term exposure to ionizing radiation as well as general characteristics of DNA repair and dose response, which can be of help to radiation protection and radiation therapy.
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